zolpidem

(redirected from Edluar)
Also found in: Dictionary.

zolpidem

 [zōl-pi´dem]
a non-benzodiazepinesedative and hypnotic used orally as the tartrate salt in the short-term treatment of insomnia.

zol·pi·dem

(zol'pi-dĕm),
A sedative/hypnotic drug useful for treating anxiety and resembling benzodiazepines in its pharmacology but differing somewhat in chemical structure. Unlike benzodiazepines, zolpidem lacks prominent anticonvulsant properties, and less tolerance may develop with its use.

zolpidem

(zōl′pə-dĕm′)
n.
A non-benzodiazepine sleep-inducing drug, C19H21N3O, used in its tartrate form to treat insomnia.

zolpidem

An imidazopyridine HYPNOTIC drug used for the short-term treatment of INSOMNIA. A brand name is Stilnoct.

zol·pi·dem

(zol'pi-dĕm)
A sedative/hypnotic drug useful for treating anxiety and resembling benzodiazepines in its pharmacology but differing somewhat in chemical structure. Unlike benzodiazepines, zolpidem lacks prominent anticonvulsant properties, and less tolerance may develop with its use.
References in periodicals archive ?
Specialty pharmaceutical company MEDA AB (STO:MEDAA ) announced today that Edluar has received registration approval in Europe.
Edluar is used for treating sleep disorders and contains zolpidem, a well-documented active ingredient.
Edluar was launched in the US market in 2009 and the launch in Canada (brand Sublinox) started in early 2012.
Zolpidem is a generic drug that is marketed under a number of different brand names, including Ambien, Zolpimist, Edluar, Hypogen, Somidem and Ivedal.
Evidence of this association was so compelling, the Food and Drug Administration recently announced that it is requiring manufacturers of Ambien, Ambien CR, Zolpimist, and Edluar, sleep aids that contain zolpidem, to lower recommended doses.
In August, Orexo said its Swedish partner Meda AB (STO: MEDA A) started the launch of jointly developed insomnia drug Edluar in the USA.
Earlier this week, Orexo said that its Swedish partner Meda AB (STO: MEDA A) had initiated the launch of their jointly developed insomnia drug Edluar in the USA.
18 August 2009 - Swedish pharmaceutical company Orexo AB (STO: ORX) said today that its local partner Meda AB (STO: MEDA A) has initiated the launch of their jointly developed insomnia drug Edluar in the USA.
In March 2009, the US Food and Drug Administration (FDA) granted marketing approval for 5-mg and 10-mg sublingual tablets of Edluar (zolpidem), formerly known as Sublinox.
"I am delighted that the FDA has approved Edluar for the treatment of short-term insomnia.